Mariotti Veronica, Greco Steven J, Mohan Ryan D, Nahas George R, Rameshwar Pranela
Department of Medicine - Hematology/Oncology, New Jersey Medical School, Rutgers School of Biomedical Sciences, E-585, 185 South Orange Avenue, Newark, NJ 07103 USA.
Stowers Institute for Medical Research, Kansas City, MO USA.
Mol Cell Ther. 2014 Aug 1;2:24. doi: 10.1186/2052-8426-2-24. eCollection 2014.
Despite ongoing research efforts and attempts to bring new drugs into trial, the prognosis for brain tumors remains poor. Patients with the most common and lethal intracranial neoplasia, glioblastoma multiforme (GBM), have an average survival of one year with combination of surgical resection, radiotherapy and temozolomide. One of the main problems in the treatment of GBM is getting drugs across the blood brain barrier (BBB) efficiently. In an attempt to solve this problem, there are ongoing experimental and clinical trials to deliver drugs within stem cells. The purpose for this method is the ease by which stem cells home to the brain. This review discusses the experimental and clinical applications of stem cells for GBM. We also discuss the different properties of stem cells. This information is important to understand why one stem cell would be advantageous over another in cell therapy. We provide an overview of the different drug delivery methods, gene-based treatments and cancer vaccines for GBM, including the stem cell subset.
尽管一直在进行研究并努力将新药带入临床试验，但脑肿瘤的预后仍然很差。患有最常见且致命的颅内肿瘤——多形性胶质母细胞瘤（GBM）的患者，通过手术切除、放疗和替莫唑胺联合治疗，平均生存期为一年。治疗GBM的主要问题之一是如何有效地使药物穿过血脑屏障（BBB）。为了解决这个问题，目前正在进行将药物递送至干细胞内的实验和临床试验。这种方法的目的是利用干细胞归巢至脑部的便利性。本综述讨论了干细胞在GBM中的实验和临床应用。我们还讨论了干细胞的不同特性。了解这些信息对于理解在细胞治疗中一种干细胞为何比另一种更具优势很重要。我们概述了针对GBM的不同药物递送方法基于基因的治疗和癌症疫苗，包括干细胞亚群。
